|
CN104761637B
(zh)
*
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
EP3415529B1
(en)
|
2007-09-26 |
2020-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
EP2275443B1
(en)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
TWI654204B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
|
EP2698431B1
(en)
*
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
JP5997151B2
(ja)
|
2011-06-30 |
2016-09-28 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
US20150050269A1
(en)
*
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
BR112014007484A2
(pt)
|
2011-09-30 |
2017-04-04 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
|
|
WO2013047752A1
(ja)
*
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
|
CA3233142A1
(en)
*
|
2011-11-30 |
2013-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
EP2813568B1
(en)
|
2012-02-09 |
2025-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
PL2814587T3
(pl)
|
2012-02-15 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Chromatografia powinowactwa oparta na receptorze Fc
|
|
WO2013125667A1
(ja)
|
2012-02-24 |
2013-08-29 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
|
KR102213535B1
(ko)
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
DK2825036T3
(en)
*
|
2012-03-16 |
2018-07-16 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified rodents to generate them
|
|
HK1200271A1
(en)
|
2012-03-16 |
2015-08-07 |
瑞泽恩制药公司 |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
HK1207654A1
(en)
|
2012-04-27 |
2016-02-05 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
EP3892638A1
(en)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
SG10202006507XA
(en)
*
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
|
SG11201500873XA
(en)
|
2012-08-24 |
2015-04-29 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc region variant
|
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
GB201302878D0
(en)
*
|
2013-02-19 |
2013-04-03 |
Argen X Bv |
Modified igG molecules
|
|
TWI636062B
(zh)
|
2013-04-02 |
2018-09-21 |
中外製藥股份有限公司 |
Fc region variant
|
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
|
CN105764922B
(zh)
|
2013-09-27 |
2020-07-17 |
中外制药株式会社 |
多肽异源多聚体的制备方法
|
|
BR112016006502A2
(pt)
|
2013-09-30 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
|
|
TWI652279B
(zh)
|
2013-11-11 |
2019-03-01 |
中外製藥股份有限公司 |
含改變的抗體可變區之抗原結合分子
|
|
AU2014358191B2
(en)
|
2013-12-04 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
|
BR112016014969A2
(pt)
|
2014-01-15 |
2018-01-23 |
Hoffmann La Roche |
polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
EP3119490B1
(en)
|
2014-03-21 |
2021-09-08 |
F. Hoffmann-La Roche AG |
In vitro prediction of in vivo half-life of antibodies
|
|
EP3142700B1
(en)
*
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
CA2946430A1
(en)
*
|
2014-06-12 |
2015-12-17 |
F. Hoffmann-La Roche Ag |
Method for selecting antibodies with modified fcrn interaction
|
|
FR3024453B1
(fr)
*
|
2014-08-01 |
2018-06-29 |
Lab Francais Du Fractionnement |
Procede de production de variants ayant un fc presentant une sialylation amelioree
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
WO2016071377A1
(en)
*
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
US10307480B2
(en)
*
|
2014-11-06 |
2019-06-04 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
|
EP3215528B1
(en)
*
|
2014-11-06 |
2019-08-07 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
|
EP4632120A3
(en)
|
2014-11-11 |
2026-01-07 |
Chugai Seiyaku Kabushiki Kaisha |
Library of antigen-binding molecules including modified antibody variable region
|
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
US9879080B2
(en)
|
2015-01-28 |
2018-01-30 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US10464999B2
(en)
|
2015-01-28 |
2019-11-05 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US10633433B2
(en)
|
2015-01-28 |
2020-04-28 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
TWI873632B
(zh)
|
2015-02-27 |
2025-02-21 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
PT3922645T
(pt)
*
|
2015-09-15 |
2025-05-29 |
Scholar Rock Inc |
¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
|
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
|
EP3390443A4
(en)
|
2015-12-18 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
CN115814077A
(zh)
|
2016-01-08 |
2023-03-21 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
|
|
MA43773B1
(fr)
*
|
2016-03-14 |
2026-01-30 |
Universitetet I Oslo |
Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
|
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
US11136405B2
(en)
*
|
2016-06-06 |
2021-10-05 |
Board Of Regents, The Unviersity Of Texas System |
BAFF-R antibodies and uses thereof
|
|
WO2017218515A1
(en)
|
2016-06-14 |
2017-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibodies and uses thereof
|
|
MX2018014375A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y metodos de uso.
|
|
FI3494134T3
(fi)
*
|
2016-08-02 |
2026-02-19 |
Visterra Inc |
Muunneltuja polypeptidejä ja niiden käyttötapoja
|
|
BR112019001902A2
(pt)
|
2016-08-05 |
2019-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
composição para profilaxia ou tratamento de doenças relacionadas à il-8
|
|
MA45919A
(fr)
*
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
US11155611B2
(en)
|
2017-01-06 |
2021-10-26 |
Scholar Rock, Inc. |
Compositions and methods for making and using anti-myostatin antibodies
|
|
EP3569615A4
(en)
*
|
2017-01-13 |
2020-07-29 |
Hanx Biopharmaceutics, Inc |
PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter
|
|
JP7191833B2
(ja)
|
2017-01-30 |
2022-12-19 |
中外製薬株式会社 |
抗スクレロスチン抗体およびその使用
|
|
CR20190403A
(es)
|
2017-01-31 |
2019-10-10 |
Hoffmann La Roche |
Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
|
|
AU2018218345B2
(en)
*
|
2017-02-10 |
2025-04-03 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
NZ756763A
(en)
|
2017-02-17 |
2023-04-28 |
Denali Therapeutics Inc |
Engineered transferrin receptor binding polypeptides
|
|
WO2018186717A1
(ko)
|
2017-04-07 |
2018-10-11 |
국민대학교 산학협력단 |
혈중 반감기 향상을 위한 항체 Fc 변이체들
|
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
|
AU2018281045A1
(en)
*
|
2017-06-05 |
2019-12-12 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
|
JP7191087B2
(ja)
|
2017-08-11 |
2022-12-16 |
リサーチ ディベロップメント ファウンデーション |
血清中半減期の増強のための操作された抗体ｆｃバリアント
|
|
CN111315213B
(zh)
|
2017-10-06 |
2023-09-12 |
普罗塞纳生物科学有限公司 |
抗甲状腺素运载蛋白抗体
|
|
PE20210042A1
(es)
|
2017-10-06 |
2021-01-08 |
Prothena Biosciences Ltd |
Metodos para detectar transtiretina
|
|
US12235261B2
(en)
|
2017-10-20 |
2025-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring cellular uptake of molecules
|
|
EP3700928A1
(en)
|
2017-10-26 |
2020-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
|
|
CA3080103A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
AU2018375356A1
(en)
|
2017-11-29 |
2020-05-14 |
Neotope Neuroscience Limited |
Lyophilized formulation of a monoclonal antibody against transthyretin
|
|
EP3720963A4
(en)
|
2017-12-05 |
2021-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
|
|
MX2020006113A
(es)
|
2017-12-13 |
2020-08-24 |
Regeneron Pharma |
Combinaciones de anticuerpos anti-c5 y usos de las mismas.
|
|
EP3746122A4
(en)
*
|
2018-02-02 |
2021-11-24 |
OncoC4, Inc. |
SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY
|
|
AU2019214865B2
(en)
|
2018-02-02 |
2025-04-10 |
OncoC4, Inc. |
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
WO2019190990A1
(en)
*
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
|
US11505610B2
(en)
|
2018-04-06 |
2022-11-22 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
CN120209132A
(zh)
*
|
2018-04-13 |
2025-06-27 |
中外制药株式会社 |
抗补体组分抗体及使用方法
|
|
JP7516254B2
(ja)
|
2018-04-18 |
2024-07-16 |
ゼンコア インコーポレイテッド |
Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
KR20210003813A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
MX2020012091A
(es)
|
2018-05-14 |
2021-04-28 |
Oncoimmune Inc |
Composiciones anti-cd24 y usos de las mismas.
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
|
|
GB201809341D0
(en)
*
|
2018-06-07 |
2018-07-25 |
Ucb Biopharma Sprl |
Multi-domain proteins with increased native state colloidal stability
|
|
JP7397444B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン－５に結合する抗体
|
|
CN112424358B
(zh)
|
2018-06-26 |
2025-07-01 |
协和麒麟株式会社 |
与细胞粘附分子3结合的抗体
|
|
EP3814373A1
(en)
|
2018-06-28 |
2021-05-05 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MX2021000532A
(es)
|
2018-07-19 |
2021-04-12 |
Regeneron Pharma |
Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
|
|
IL280475B2
(en)
|
2018-08-01 |
2026-04-01 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
|
|
IL317002A
(en)
|
2018-08-10 |
2025-01-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CD137 antigen binding molecule and use thereof
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
MX2021004994A
(es)
|
2018-10-30 |
2021-06-15 |
Alexion Pharma Inc |
Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
|
|
JP7410143B2
(ja)
*
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
CN113227131B
(zh)
|
2018-12-20 |
2025-03-04 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
|
AU2020273072B2
(en)
|
2019-04-10 |
2026-01-22 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying Fc region-modified antibody
|
|
GB2589049C
(en)
*
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
JPWO2020213724A1
(enExample)
*
|
2019-04-19 |
2020-10-22 |
|
|
|
CN114096562B
(zh)
|
2019-05-15 |
2025-02-21 |
中外制药株式会社 |
抗原结合分子、药物组合物和方法
|
|
CA3142886A1
(en)
*
|
2019-06-06 |
2020-12-10 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
CN114786732A
(zh)
*
|
2019-06-06 |
2022-07-22 |
神话治疗股份有限公司 |
抗原结合蛋白构建体及其用途
|
|
CN114746115A
(zh)
*
|
2019-06-07 |
2022-07-12 |
神话治疗股份有限公司 |
抗原结合蛋白构建体及其用途
|
|
CA3146379A1
(en)
*
|
2019-07-08 |
2021-01-14 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
US20220281984A1
(en)
*
|
2019-07-30 |
2022-09-08 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
AU2020330307A1
(en)
*
|
2019-08-12 |
2022-03-17 |
CSL Innovation Pty Ltd |
Complement C2 binding proteins and uses thereof
|
|
CN114746120B
(zh)
|
2019-10-03 |
2024-07-30 |
Atyr医药公司 |
包含抗nrp2抗体的组合物和方法
|
|
CN114728175A
(zh)
*
|
2019-10-04 |
2022-07-08 |
神话治疗股份有限公司 |
抗原结合性蛋白构建体和其用途
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US12600778B2
(en)
*
|
2019-10-31 |
2026-04-14 |
The Research Foundation For The State University Of New York |
Rage antibodies, fragments and uses thereof
|
|
WO2021122733A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
US20230072197A1
(en)
*
|
2020-01-29 |
2023-03-09 |
Korea University Research And Business Foundation |
Ph-sensitive fc variants
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
EP4133269A1
(en)
*
|
2020-04-08 |
2023-02-15 |
F. Hoffmann-La Roche AG |
Large molecule unspecific clearance assay
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Ｆｃポリペプチド
|
|
CN120309734A
(zh)
|
2021-01-13 |
2025-07-15 |
威特拉公司 |
人源化补体5a受体1抗体和其使用方法
|
|
EP4494660A3
(en)
*
|
2021-02-03 |
2025-04-16 |
Mythic Therapeutics, Inc. |
Anti-met antibodies and uses thereof
|
|
WO2022263501A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
TW202527987A
(zh)
|
2021-06-25 |
2025-07-16 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
CN115572331A
(zh)
*
|
2021-07-06 |
2023-01-06 |
联邦生物科技(珠海横琴)有限公司 |
一种具有增强FcRn受体结合的突变子
|
|
CA3229487A1
(en)
*
|
2021-08-20 |
2023-02-23 |
Adam WAICKMAN |
Iga monoclonal antibodies for treating flavivirus infection
|
|
WO2024092031A1
(en)
|
2022-10-25 |
2024-05-02 |
Seismic Therapeutic, Inc. |
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
|
|
AU2023413166A1
(en)
|
2022-12-22 |
2025-07-03 |
Scholar Rock, Inc. |
Selective and potent inhibitory antibodies of myostatin activation
|
|
AU2024242538A1
(en)
*
|
2023-03-24 |
2025-10-30 |
Paragon Therapeutics, Inc. |
Fc fragments that bind fcrn and methods of use
|
|
US12286475B2
(en)
|
2023-07-31 |
2025-04-29 |
Sanofi |
Anti-GPRC5D antibodies and compositions
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
WO2025260124A1
(en)
*
|
2024-06-17 |
2025-12-26 |
CSL Innovation Pty Ltd |
MULTIFUNCTIONAL FcRn ANTAGONISTS AND USES THEREOF
|
|
FR3167160A1
(fr)
|
2024-10-08 |
2026-04-10 |
Alga Biologics |
Immunoglobulines avec affinite augmentee pour le fcrn
|
|
CN120365429B
(zh)
*
|
2025-06-30 |
2025-09-05 |
上海交通大学医学院附属仁济医院 |
Cd70特异性纳米抗体、分子影像探针及其制备方法和应用
|